Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1995 Aug;54(8):674–677. doi: 10.1136/ard.54.8.674

Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study.

M A van Leeuwen 1, J Westra 1, P C Limburg 1, P L van Riel 1, M H van Rijswijk 1
PMCID: PMC1009966  PMID: 7677445

Abstract

OBJECTIVE--To evaluate the clinical significance of interleukin-6 (IL-6) measurements in relation to laboratory and clinical measures of disease activity and radiological progression in early rheumatoid arthritis (RA). METHODS--A prospective study was performed in 51 patients with early RA during the first three years of the disease, with monthly clinical and laboratory assessments and biannual radiographs of the hands and feet. IL-6 was measured by enzyme linked immunosorbent assay (ELISA). Cross sectional (n = 51) and longitudinal (n = 20) correlations between plasma IL-6 concentrations and values of C reactive protein (CRP), serum amyloid A protein (SAA), erythrocyte sedimentation rate (ESR), haemoglobin (Hb), platelets, and joint scores were calculated, and correlations made between time integrated values of IL-6, CRP and ESR, and radiological progression over three years (n = 20). RESULTS--Significant correlations were found between IL-6 and the acute phase response and platelets, but variable results were obtained for the correlation between IL-6 and Hb. In contrast to a significant correlation between time integrated values of CRP or ESR and radiological progression, time integrated values of IL-6 did not correlate with radiological progression over three years follow up. CONCLUSION--The course of disease activity and the radiological progression of joint damage are better reflected by CRP, SAA, and ESR values than by plasma IL-6 concentrations, particularly in stages of low disease activity.

Full text

PDF
674

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arend W. P., Dayer J. M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990 Mar;33(3):305–315. doi: 10.1002/art.1780330302. [DOI] [PubMed] [Google Scholar]
  2. Dasgupta B., Corkill M., Kirkham B., Gibson T., Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol. 1992 Jan;19(1):22–25. [PubMed] [Google Scholar]
  3. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251–7255. doi: 10.1073/pnas.84.20.7251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Guerne P. A., Zuraw B. L., Vaughan J. H., Carson D. A., Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest. 1989 Feb;83(2):585–592. doi: 10.1172/JCI113921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hollen C. W., Henthorn J., Koziol J. A., Burstein S. A. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol. 1991 Oct;79(2):286–290. doi: 10.1111/j.1365-2141.1991.tb04534.x. [DOI] [PubMed] [Google Scholar]
  6. Holt I., Cooper R. G., Denton J., Meager A., Hopkins S. J. Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol. 1992 Nov;31(11):725–733. doi: 10.1093/rheumatology/31.11.725. [DOI] [PubMed] [Google Scholar]
  7. Madhok R., Crilly A., Watson J., Capell H. A. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993 Mar;52(3):232–234. doi: 10.1136/ard.52.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Means R. T., Jr, Krantz S. B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992 Oct 1;80(7):1639–1647. [PubMed] [Google Scholar]
  9. Sharp J. T., Young D. Y., Bluhm G. B., Brook A., Brower A. C., Corbett M., Decker J. L., Genant H. K., Gofton J. P., Goodman N. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985 Dec;28(12):1326–1335. doi: 10.1002/art.1780281203. [DOI] [PubMed] [Google Scholar]
  10. de Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G. R., Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991 Sep;34(9):1158–1163. doi: 10.1002/art.1780340912. [DOI] [PubMed] [Google Scholar]
  11. van Gameren M. M., Willemse P. H., Mulder N. H., Limburg P. C., Groen H. J., Vellenga E., de Vries E. G. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood. 1994 Sep 1;84(5):1434–1441. [PubMed] [Google Scholar]
  12. van Leeuwen M. A., Westra J., Limburg P. C., van Riel P. L., van Rijswijk M. H. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis. 1995 Jan;54(1):33–38. doi: 10.1136/ard.54.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. van Leeuwen M. A., van der Heijde D. M., van Rijswijk M. H., Houtman P. M., van Riel P. L., van de Putte L. B., Limburg P. C. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol. 1994 Mar;21(3):425–429. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES